Allergen immunotherapy for birch pollen-allergic patients: recent advances

As of today, allergen immunotherapy is performed with aqueous natural allergen extracts. Recombinant allergen vaccines are not yet commercially available, although they could provide patients with well-defined and highly consistent drug substances. As Bet v 1 is the major allergen involved in birch...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2016-05, Vol.8 (5), p.555-567
Main Authors: Moingeon, Philippe, Floch, Véronique Bordas-Le, Airouche, Sabi, Baron-Bodo, Véronique, Nony, Emmanuel, Mascarell, Laurent
Format: Article
Language:English
Subjects:
Allergens
Allergies
Asthma
Bet v 1 antigen
birch pollen
Calcium phosphates
Cholera
Immunization
Immunotherapy
Pollen
recombinant Bet v 1
Rhinoconjunctivitis
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As of today, allergen immunotherapy is performed with aqueous natural allergen extracts. Recombinant allergen vaccines are not yet commercially available, although they could provide patients with well-defined and highly consistent drug substances. As Bet v 1 is the major allergen involved in birch pollen allergy, with more than 95% of patients sensitized to this allergen, pharmaceutical-grade recombinant Bet v 1-based vaccines were produced and clinically tested. Herein, we compare the clinical results and modes of action of treatments based on either a birch pollen extract or recombinant Bet v 1 expressed as hypoallergenic or natural-like molecules. We also discuss the future of allergen immunotherapy with improved drugs intended for birch pollen-allergic patients suffering from rhinoconjunctivitis.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2015-0027